Corbus Pharmaceuticals Q2 2025 Net Loss $17.7M, Pipeline on Track for Data Readouts H2 2025

Corbus Pharmaceuticals Holdings, Inc.

2025-Q2 EPS reported -$2.83 vs consensus -$1.54 ▼ miss (-83.5%)

Net loss for Q2 2025 was $17.7 million ($1.44 per share), compared to $10.0 million loss in Q2 2024.
Cash and investments totaled $116.6 million as of June 30, 2025, expected to fund operations through Q2 2027.
Phase 1/2 dose expansion data for Nectin-4 ADC CRB-701 to be presented at ESMO 2025 in October.
Obesity drug CRB-913 initiated multiple ascending dose portion; SAD/MAD data expected later in 2025.
FDA granted Fast Track designation for CRB-701 in relapsed/refractory metastatic cervical cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.